NZ630596A - Methods for treatment of alport syndrome - Google Patents

Methods for treatment of alport syndrome

Info

Publication number
NZ630596A
NZ630596A NZ630596A NZ63059613A NZ630596A NZ 630596 A NZ630596 A NZ 630596A NZ 630596 A NZ630596 A NZ 630596A NZ 63059613 A NZ63059613 A NZ 63059613A NZ 630596 A NZ630596 A NZ 630596A
Authority
NZ
New Zealand
Prior art keywords
treatment
alport syndrome
methods
modified oligonucleotide
alport
Prior art date
Application number
NZ630596A
Other languages
English (en)
Inventor
Balkrishen Bhat
Jeremy Duffield
Deidre Mackenna
Original Assignee
Regulus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regulus Therapeutics Inc filed Critical Regulus Therapeutics Inc
Publication of NZ630596A publication Critical patent/NZ630596A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/313—Phosphorodithioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NZ630596A 2012-10-09 2013-10-08 Methods for treatment of alport syndrome NZ630596A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261711514P 2012-10-09 2012-10-09
US201361779137P 2013-03-13 2013-03-13
PCT/US2013/063884 WO2014058881A1 (en) 2012-10-09 2013-10-08 Methods for treatment of alport syndrome

Publications (1)

Publication Number Publication Date
NZ630596A true NZ630596A (en) 2017-05-26

Family

ID=49382663

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ630596A NZ630596A (en) 2012-10-09 2013-10-08 Methods for treatment of alport syndrome

Country Status (34)

Country Link
US (8) US9012423B2 (cg-RX-API-DMAC7.html)
EP (2) EP2906698B1 (cg-RX-API-DMAC7.html)
JP (4) JP6272880B2 (cg-RX-API-DMAC7.html)
KR (4) KR20230136686A (cg-RX-API-DMAC7.html)
CN (1) CN104718295B (cg-RX-API-DMAC7.html)
AR (1) AR092940A1 (cg-RX-API-DMAC7.html)
AU (3) AU2013329427B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015007709B1 (cg-RX-API-DMAC7.html)
CA (1) CA2885605A1 (cg-RX-API-DMAC7.html)
CL (1) CL2015000873A1 (cg-RX-API-DMAC7.html)
CR (1) CR20150236A (cg-RX-API-DMAC7.html)
CY (1) CY1122479T1 (cg-RX-API-DMAC7.html)
DK (1) DK2906698T3 (cg-RX-API-DMAC7.html)
EA (1) EA201590711A1 (cg-RX-API-DMAC7.html)
ES (2) ES2753174T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20191948T1 (cg-RX-API-DMAC7.html)
HU (1) HUE045858T2 (cg-RX-API-DMAC7.html)
IL (2) IL237768B (cg-RX-API-DMAC7.html)
LT (1) LT2906698T (cg-RX-API-DMAC7.html)
MX (1) MX356340B (cg-RX-API-DMAC7.html)
MY (1) MY183921A (cg-RX-API-DMAC7.html)
NZ (1) NZ630596A (cg-RX-API-DMAC7.html)
PH (1) PH12015500781B1 (cg-RX-API-DMAC7.html)
PL (1) PL2906698T3 (cg-RX-API-DMAC7.html)
PT (1) PT2906698T (cg-RX-API-DMAC7.html)
RS (1) RS60014B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201502748RA (cg-RX-API-DMAC7.html)
SI (1) SI2906698T1 (cg-RX-API-DMAC7.html)
TN (1) TN2015000099A1 (cg-RX-API-DMAC7.html)
TW (1) TWI641388B (cg-RX-API-DMAC7.html)
UA (1) UA116639C2 (cg-RX-API-DMAC7.html)
UY (1) UY35069A (cg-RX-API-DMAC7.html)
WO (1) WO2014058881A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201502087B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1838852A2 (en) 2004-11-12 2007-10-03 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
PL2702155T3 (pl) 2011-04-25 2017-09-29 Regulus Therapeutics Inc. Związki mikroRNA i sposoby modulowania aktywności miR-21
IN2014DN09134A (cg-RX-API-DMAC7.html) 2012-04-25 2015-05-22 Regulus Therapeutics Inc
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
WO2015061536A1 (en) 2013-10-25 2015-04-30 Regulus Therapeutics Inc. Microrna compounds and methods for modulating mir-21 activity
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
US20180207240A1 (en) * 2014-07-25 2018-07-26 Goldfinch Biopharma, Inc. Collagen iv replacement
EP3182989B1 (en) * 2014-08-21 2021-04-14 Stealth Biotherapeutics Corp Peptide d-arg-2',6'-dmt-lys-phe-nh2 for treating alport syndrome
CN107109411B (zh) 2014-10-03 2022-07-01 冷泉港实验室 核基因输出的定向增加
KR102422625B1 (ko) 2015-10-09 2022-07-20 유니버시티 오브 사우스앰톤 유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
KR102604132B1 (ko) 2015-12-14 2023-11-17 콜드스프링하버러보러토리 상염색체 우성 정신 지체 5 및 드라베 증후군의 치료를 위한 안티센스 올리고머
BR112019009256A2 (pt) 2016-11-08 2019-07-16 Reata Pharmaceuticals Inc métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo
EP3548005A4 (en) 2016-11-29 2020-06-17 Puretech Health LLC Exosomes for delivery of therapeutic agents
AU2017386771A1 (en) * 2016-12-28 2019-06-20 Daiichi Sankyo Company, Limited Therapeutic drug for Alport's syndrome
MA50749A (fr) * 2017-05-04 2020-03-11 Sanofi Sa Méthodes de traitement du syndrome d'alport
JP2020524490A (ja) 2017-06-06 2020-08-20 ザイマージェン インコーポレイテッド Ｅｓｃｈｅｒｉｃｈｉａ Ｃｏｌｉを改良するためのＨＴＰゲノム操作プラットフォーム
WO2018226900A2 (en) 2017-06-06 2018-12-13 Zymergen Inc. A htp genomic engineering platform for improving fungal strains
CN111278991B (zh) 2017-08-25 2022-04-01 斯托克制药公司 用于治疗病况和疾病的反义寡聚体
RS66633B1 (sr) 2017-10-23 2025-08-29 Stoke Therapeutics Inc Antisens oligomeri za lečenje bolesti i stanja na bazi besmisleno posredovanog raspadanja rnk
US12060558B2 (en) 2018-05-04 2024-08-13 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
KR20210088615A (ko) 2018-10-31 2021-07-14 지머젠 인코포레이티드 Dna 라이브러리의 다중 결정적 어셈블리
US11053515B2 (en) 2019-03-08 2021-07-06 Zymergen Inc. Pooled genome editing in microbes
JP2022524043A (ja) 2019-03-08 2022-04-27 ザイマージェン インコーポレイテッド 微生物の反復ゲノム編集
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
CN115867657A (zh) 2020-05-11 2023-03-28 斯托克制药公司 用于治疗疾患和疾病的opa1反义寡聚物
KR20250008750A (ko) * 2022-05-09 2025-01-15 칼리디타스 테라퓨틱스 스위스 에스에이 알포트 증후군의 치료에서의 용도를 위한 nox 억제제
WO2024238950A1 (en) * 2023-05-18 2024-11-21 Keros Therapeutics, Inc. Methods of using activin receptor type ii variants
WO2025110217A1 (ja) * 2023-11-22 2025-05-30 国立大学法人東海国立大学機構 嚢胞性腎疾患の予防及び／又は治療剤

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200003432T2 (tr) * 1998-05-22 2001-03-21 Boys Town National Research Hospital Alfa1beta1 birleştirici alıcı önleyicilerinin kullanılması ve böbrek hastalığının tedavisinde TGF-beta1 önleyicileri.
KR100574597B1 (ko) * 1998-05-22 2006-04-28 보이스 타운 내셔널 리서치 호스피탈 α1β1 인테그린 수용체 저해제 및 ＴＧＦ-β1 저해제의신장 질환의 치료용 용도
US20060008817A1 (en) 2000-12-08 2006-01-12 Invitrogen Corporation Methods and compositions for generating recombinant nucleic acid molecules
CA2462144C (en) 2001-09-28 2016-09-20 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Micro-rna molecules
US7585501B2 (en) * 2002-06-14 2009-09-08 Stowers Institute For Medical Research Compositions and methods for treating kidney disease
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
ITMI20032528A1 (it) * 2003-12-19 2005-06-20 Francesco Santangelo Uso di cistina o di cisteina per la prevenzione e il
US7585550B2 (en) 2004-02-02 2009-09-08 College Of William And Mary Process for modifying polymeric surfaces using deep UV irradiation
EP1771563A2 (en) 2004-05-28 2007-04-11 Ambion, Inc. METHODS AND COMPOSITIONS INVOLVING MicroRNA
US7582744B2 (en) 2004-08-10 2009-09-01 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides
WO2006029173A2 (en) 2004-09-08 2006-03-16 Boys Town National Research Hospital Treatment of glomerular basement membrane disease involving matrix metalloproteinase-12
EP1838852A2 (en) 2004-11-12 2007-10-03 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
WO2006069584A2 (en) 2004-12-29 2006-07-06 Exiqon A/S NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs
US6995235B1 (en) 2005-05-02 2006-02-07 Univation Technologies, Llc Methods of producing polyolefins and films therefrom
DK1931780T3 (en) * 2005-08-29 2016-01-25 Regulus Therapeutics Inc Antisense-forbindelser med forøget anti-microrna-aktivitet
JP5213723B2 (ja) 2006-01-27 2013-06-19 アイシス ファーマシューティカルズ， インコーポレーテッド マイクロｒｎａの調節に使用するためのオリゴマー化合物及び組成物
NZ571569A (en) 2006-04-03 2011-09-30 Santaris Pharma As Pharmaceutical compositions comprising anti miRNA antisense oligonucleotides
EP2007889A2 (en) 2006-04-03 2008-12-31 Santaris Pharma A/S Pharmaceutical compositions comprising anti-mirna antisense oligonucleotides
CA2927045A1 (en) 2006-10-03 2008-04-10 Muthiah Manoharan Lipid containing formulations
JP2010505427A (ja) 2006-10-09 2010-02-25 ジュリアス−マキシミリアンズ−ユニベルシタット ワーズブルグ 心疾患の診断及び治療用マイクロＲＮＡ（ｍｉＲＮＡ）
AU2007333107A1 (en) 2006-12-08 2008-06-19 Asuragen, Inc. miR-21 regulated genes and pathways as targets for therapeutic intervention
WO2008086807A2 (en) 2007-01-19 2008-07-24 Exiqon A/S Mediated cellular delivery of lna oligonucleotides
US20100261175A1 (en) 2007-06-15 2010-10-14 Exiqon A/S Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
US20080317725A1 (en) * 2007-06-20 2008-12-25 Baum Seth J Compositions and methods of treating chronic kidney disease
MX2010003299A (es) 2007-10-04 2010-04-14 Santaris Pharma As Oligonucleotidos muy cortos (micromirs).
JP5535076B2 (ja) 2007-10-29 2014-07-02 レグルス・セラピューティクス・インコーポレイテッド 肝臓癌を治療するための標的化ミクロｒｎａ
US20110257244A1 (en) 2008-01-18 2011-10-20 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof
NZ587178A (en) * 2008-02-08 2011-11-25 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
EP2096171A1 (en) 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
CA2717792A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
AU2010218147A1 (en) 2009-02-26 2011-10-20 The Government Of The United States Of America As Represented By The Secretary Of The Dept. Of Health & Human Services MicroRNAs in never-smokers and related materials and methods
AU2010258875A1 (en) 2009-06-08 2012-01-19 Miragen Therapeutics Chemical modification motifs for miRNA inhibitors and mimetics
WO2011126842A2 (en) * 2010-03-30 2011-10-13 Regulus Therapeutics Inc. Targeting micrornas for the treatment of cardiac disorders
PL2702155T3 (pl) 2011-04-25 2017-09-29 Regulus Therapeutics Inc. Związki mikroRNA i sposoby modulowania aktywności miR-21
WO2013013165A2 (en) 2011-07-21 2013-01-24 The Trustees Of The University Of Pennsylvania Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus
IN2014DN09134A (cg-RX-API-DMAC7.html) 2012-04-25 2015-05-22 Regulus Therapeutics Inc
CN107236735B (zh) 2012-06-21 2019-11-08 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
US9725721B2 (en) 2012-09-26 2017-08-08 Mirrx Therapeutics Oligomers with improved off-target profile
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта

Also Published As

Publication number Publication date
US20180298385A1 (en) 2018-10-18
EP2906698A1 (en) 2015-08-19
US20140100263A1 (en) 2014-04-10
US9012423B2 (en) 2015-04-21
KR20200118245A (ko) 2020-10-14
CN104718295B (zh) 2020-03-13
CN104718295A (zh) 2015-06-17
PH12015500781A1 (en) 2015-06-15
KR20150064072A (ko) 2015-06-10
HUE045858T2 (hu) 2020-01-28
HK1212378A1 (en) 2016-06-10
KR20230136686A (ko) 2023-09-26
CA2885605A1 (en) 2014-04-17
AU2019210494A1 (en) 2019-08-15
AU2021269404A1 (en) 2021-12-16
TN2015000099A1 (en) 2016-06-29
US20220098582A1 (en) 2022-03-31
EP3620522A1 (en) 2020-03-11
CR20150236A (es) 2015-06-30
CL2015000873A1 (es) 2015-08-14
US20200283765A1 (en) 2020-09-10
US9359609B2 (en) 2016-06-07
MY183921A (en) 2021-03-17
US20160319283A1 (en) 2016-11-03
US20240167032A1 (en) 2024-05-23
SI2906698T1 (sl) 2019-11-29
AR092940A1 (es) 2015-05-06
AU2013329427A1 (en) 2015-04-02
SG11201502748RA (en) 2015-05-28
EA201590711A1 (ru) 2015-07-30
DK2906698T3 (da) 2019-11-04
KR20220005634A (ko) 2022-01-13
BR112015007709A2 (pt) 2017-08-08
PH12015500781B1 (en) 2015-06-15
KR102349184B1 (ko) 2022-01-07
LT2906698T (lt) 2019-11-11
AU2013329427B2 (en) 2019-05-02
ZA201502087B (en) 2016-06-29
EP2906698B1 (en) 2019-07-31
UA116639C2 (uk) 2018-04-25
MX2015004460A (es) 2015-11-23
KR102165189B1 (ko) 2020-10-14
RS60014B1 (sr) 2020-04-30
CY1122479T1 (el) 2021-01-27
IL237768B (en) 2018-10-31
JP2015536301A (ja) 2015-12-21
JP2018080190A (ja) 2018-05-24
JP6272880B2 (ja) 2018-01-31
MX356340B (es) 2018-05-23
IL262200A (en) 2018-11-29
JP2022110140A (ja) 2022-07-28
US9688986B2 (en) 2017-06-27
ES2960488T3 (es) 2024-03-05
EP3620522B1 (en) 2023-07-26
PL2906698T3 (pl) 2020-05-18
BR112015007709B1 (pt) 2022-05-17
US20170369879A1 (en) 2017-12-28
WO2014058881A1 (en) 2014-04-17
US9970011B2 (en) 2018-05-15
PT2906698T (pt) 2019-11-05
TWI641388B (zh) 2018-11-21
JP2020073479A (ja) 2020-05-14
UY35069A (es) 2014-04-30
TW201420120A (zh) 2014-06-01
ES2753174T3 (es) 2020-04-07
US20150299704A1 (en) 2015-10-22
HRP20191948T1 (hr) 2020-04-03

Similar Documents

Publication Publication Date Title
NZ630596A (en) Methods for treatment of alport syndrome
MX354267B (es) Nucléosidos, nucleótidos, y ácidos nucleicos modificados, y usos de los mismos.
PH12015501423A1 (en) Substituted nucleosides, nucleotides and analogs thereof
PH12016500660A1 (en) Substituted nucleosides, nucleotides and analogs thereof
HK1203513A1 (en) Methods of preparing substituted nucleotide analogs
NZ631537A (en) Compositions and methods for modulating apolipoprotein c-iii expression
UA117098C2 (uk) Сполука, що містить модифікований олігонуклеотид
EA201170465A1 (ru) Способы лечения прогрессирующего множественного склероза
ZA201404486B (en) Substituted nucleosides, nucleotides and analogs thereof
WO2014028429A3 (en) Enzymes and polymerases for the synthesis of rna
MX2014004862A (es) Formulaciones de polimero acrilico.
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
ZA201404444B (en) 4'-azido,3'-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
MX357656B (es) Alfa-1-microglobulina para usarse en tratamiento de enfermedades relacionadas a mitocondrias.
ZA201503366B (en) Heat treatment of carbonaceous waste, improved by the choice of injected gases
UA103197C2 (uk) Застосування ніфуртимоксу для лікування хвороб, спричинених трихомонадами
MX368084B (es) siRNA Y SU USO EN LA PREPARACIÓN DE UN MEDICAMENTO PARA USARSE EN UN MÉTODO PARA EL TRATAMIENTO DE UN TRANSTORNO OCULAR.
IN2015DN03944A (cg-RX-API-DMAC7.html)
NZ748483A (en) Methods for treatment of alport syndrome
NZ755117A (en) Compositions and methods for modulating hbv and ttr expression
UA59664U (ru) Способ лечения больных фелинозом
NZ622558A (en) Hiv replication inhibitors
CR20110540S (es) Gabinete de barra para estacionamiento
UA97741C2 (ru) Способ восстановления кожных покровов при глубоких распространенных ожогах микроаутодермотрансплантатами

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 OCT 2018 BY DENNEMEYER + CO

Effective date: 20171011

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 OCT 2019 BY THOMSON REUTERS

Effective date: 20180917

ASS Change of ownership

Owner name: SANOFI, FR

Effective date: 20190731

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 OCT 2020 BY CPA GLOBAL

Effective date: 20190829

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 OCT 2021 BY CPA GLOBAL

Effective date: 20200903

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 OCT 2022 BY CPA GLOBAL

Effective date: 20210902

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 OCT 2023 BY CPA GLOBAL

Effective date: 20220902

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 OCT 2024 BY CPA GLOBAL

Effective date: 20230831

LAPS Patent lapsed